Related Experiment Video

Updated: Aug 22, 2025

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
14:57

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

94.3K

Modulators of ASIC1a and its potential as a therapeutic target for age-related diseases

Ren-Peng Zhou1, Hong-Yu Liang2, Wei-Rong Hu3

  • 1Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei 230601, China; The Key Laboratory of Anti-inflammatory and Immune Medicine, Anhui Medical University, Ministry of Education, Hefei 230032, China.

Ageing Research Reviews
|November 12, 2022
PubMed

Insights

As the global population ages, age-related diseases are increasing. Acid-sensing ion channel 1a (ASIC1a) is implicated in these conditions and presents a promising new therapeutic target for drug development.

Area of Science:

  • Biomedical Science
  • Neuroscience
  • Pharmacology

Background:

  • Age-related diseases are increasing globally, characterized by tissue degeneration and cellular apoptosis.
  • Current treatments for many age-related diseases are limited, highlighting the need for novel therapeutic targets.
  • Acid-sensing ion channel 1a (ASIC1a) is activated by acidic conditions and influences processes like inflammation and ischemia.

Purpose of the Study:

  • To review the properties, distribution, and physiological functions of ASIC1a.
  • To summarize the pharmacological characteristics of ASIC1a.
  • To evaluate ASIC1a as a potential therapeutic target for age-related diseases.

Main Methods:

  • Literature review of ASIC1a channel properties and function.
  • Analysis of existing pharmacological data on ASIC1a.
  • Synthesis of evidence linking ASIC1a to age-related disease pathogenesis.

Main Results:

  • ASIC1a exhibits specific channel properties, distribution patterns, and physiological roles.
  • ASIC1a has distinct pharmacological profiles that can be targeted.
  • ASIC1a is significantly involved in the development of various age-related diseases, including stroke and neurodegenerative disorders.

Conclusions:

  • ASIC1a is a key player in the pathophysiology of age-related diseases.
  • Targeting ASIC1a offers a promising strategy for developing new treatments.
  • Further research into ASIC1a pharmacology is warranted for therapeutic applications.
Keywords:
Acid-sensing ion channelAge-related diseaseDegenerationRheumatoid arthritisStroke

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.4K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.6K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
406
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
485
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
245
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
749
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19